Loading data for ACRV — first visit, this takes a few seconds.
Acrivon Therapeutics, Inc.
1.96 -0.04 (-2.00%)
1.89 +2.16%
- Capitalización de mercado
- $79.28M
- Volumen
- 208K
- Próxima fecha de resultados
- Aug 14, 2025
Acrivon Therapeutics, Inc. (ACRV): cotización, análisis y datos
Valor intrínseco
Ver planes →Pronóstico del analista
Previsiones bursátiles →Últimos resultados
| Reportado | Vs. estimación | Cambio interanual | |
|---|---|---|---|
| Ingresos | $0 | n/a | n/a |
| EPS | -$0.43 | +$0.07 | +21.82% |
Métricas
- Precio de compra
- 1.14
- Ingresos (TTM)
- n/a
- Beneficio neto (TTM)
- -74.2M
- 1.93
- -1.88
- n/a
- -1.1
- P/B (TTM)
- 0.91
- P/S (TTM)
- n/a
- Fecha de resultados
- Aug 14, 2025
- Precio de venta
- 2.06
- Volumen
- 208,218
- Volumen medio (20D)
- 383,909
- Abierto
- 1.98
- Anterior Cerrar
- 2.00
- Rango del día
- 1.94 - 1.99
- Rango de 52 semanas
- 1.27 - 3.56
- analista
- n/a
- Precio objetivo
- n/a
- Dividendos
- n/a
- Fecha ex dividendo
- n/a
Acerca de Acrivon Therapeutics, Inc.
Ver perfil →Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 for the treatment of patients with endometrial and platinum-resistant ovarian cancer, and SCCs, such as SCCHN and anal cancer. The company is also developing ACR-2316, a dual WEE1 and PKMYT1 inhibitor small molecule candidate; and a preclinical stage AP3-and co-crystallography-based preclinical cell cycle program. The company was incorporated in 2018 and is based in Watertown, Massachusetts.
Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 for the treatment of patients with endometrial and platinum-resistant ovarian cancer, and SCCs, such as SCCHN and anal cancer. The company is also developing ACR-2316, a dual WEE1 and PKMYT1 inhibitor small molecule candidate; and a preclinical stage AP3-and co-crystallography-based preclinical cell cycle program. The company was incorporated in 2018 and is based in Watertown, Massachusetts.
Industria Biotechnology
Sector Healthcare
IPO Fecha Nov 15, 2022
Empleados 74
Bolsa de Valores NasdaqGM
Símbolo bursátil ACRV
Sitio web https://acrivon.com